RxDoctor Payments Data

Kelsey Dowell, DO

Family Medicine · Rochester, MNNPI 1619358074

Payments from drug & device makers

$904in general payments, 2019–2025

Across 56 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$219
  • AstraZeneca$192
  • Boehringer Ingelheim$167
  • Novartis$93
  • Amgen$44
  • Merck$29
  • plus $160 from 9 others

What the payments were for

  • Food & beverage$904100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$904 in reported general payments places this provider in the 90th percentile of 1,162 family medicine providers in Minnesota.

See all family medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$33,016
Medicare patients
209
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$68,091
OzempicSemaglutide61$62,388
JardianceEmpagliflozin29$35,742
TrulicityDulaglutide18$28,059
XareltoRivaroxaban16$25,430
MounjaroTirzepatide21$24,462
JanuviaSitagliptin Phosphate24$19,591
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,883
Atorvastatin Calcium309$4,420
Levothyroxine Sodium190$2,628
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,608
Gabapentin132$2,515
Rosuvastatin Calcium165$2,483
Omeprazole180$2,475
Novolog FlexpenInsulin Aspart12$2,377

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$219$62,38861 claims
Lilly USA, LLCTrulicity, Mounjaro$11$52,52239 claims
Boehringer IngelheimJardiance$167$35,74229 claims
Johnson & JohnsonXarelto$25$25,43016 claims
MerckJanuvia$29$19,59124 claims
GSKTrelegy Ellipta$26$11,88314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,162 family medicine providers in Minnesota.

Other family medicine in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →